Home › Funds › Franklin Templeton › Franklin Genomic Advancements ETF
Fund family: Franklin Templeton · Filed by Franklin Templeton ETF Trust (CIK 1655589) · SEC series S000067393
Ticker: HELX (C000216720)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 562 with, 7 against, 0 abstentions (not counted as with management). Shareholder proposals: 6 FOR, 1 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Franklin Templeton’s manager page (151,616 ballot items across 70 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Franklin Templeton | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 89.7% | 524 | 90.1% | 113,225 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 8.3% | 1,123 |
Each ballot item this fund voted is set against the votes of the other Franklin Templeton funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Franklin Templeton funds on 2 items (0.9% of the 223 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Franklin Templeton funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | 2026-05-05 | Shareholder Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director | For | AGAINST — 7 of 8 Franklin Templeton funds | Against | Not approved, 27.6% support |
| United Therapeutics Corporation | 2026-06-26 | Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan. | For | AGAINST — 3 of 4 Franklin Templeton funds | For | Passed (calculated), 72.0% support |
Download all 2 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 80.7% of this fund’s 569 such votes could be given a sector; the other 110 (19.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 374 | 6 | 1.6% |
| Industrials | 40 | 1 | 2.5% |
| Technology | 31 | 0 | 0.0% |
| Consumer Staples | 14 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 339 | 0 |
| Audit-related | 59 | 0 |
| Say-on-Pay | 59 | 0 |
| Compensation | 44 | 0 |
| Corporate Governance | 40 | 5 |
| Capital Structure | 30 | 0 |
| Extraordinary Transactions | 4 | 0 |
| Shareholder Rights and Defenses | 3 | 1 |
| Other Social Issues | 2 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Guardant Health, Inc. | June 17, 2026 | $5M | 5 | 0 |
| Natera, Inc. | June 11, 2026 | $4M | 8 | 0 |
| Adaptive Biotechnologies Corporation | June 5, 2026 | $3M | 4 | 0 |
| Krystal Biotech, Inc. | May 15, 2026 | $3M | 5 | 0 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $2M | 11 | 0 |
| United Therapeutics Corporation | June 26, 2026 | $2M | 15 | 0 |
| BridgeBio Pharma, Inc. | June 22, 2026 | $2M | 7 | 0 |
| Medpace Holdings, Inc. | May 15, 2026 | $2M | 11 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 15, 2026 | Medpace Holdings, Inc. | Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| April 23, 2026 | IQVIA Holdings Inc. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | For | Against |
| April 21, 2026 | Bio-Rad Laboratories, Inc. | Stockholder proposal regarding dual class capital structure. Shareholder proposal | For | Against |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | For | Against |
580 ballot items at 63 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Franklin Genomic Advancements ETF (HELX) voted at 63 shareholder meetings of 60 companies, on 580 ballot items in all. Where management made a recommendation, the fund followed it on 98.8% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals about as often as Franklin Templeton's funds as a whole (89.7% against 90.1%). It voted differently from most Franklin Templeton funds on 2 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Franklin Templeton’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.